-
公开(公告)号：US08748375B2
公开(公告)日：2014-06-10
申请号：US13256779
申请日：2010-03-17
CPC分类号： A61K38/22
摘要： Methods for affecting body composition include the use of amylin agonists, such as pramlintide or davalintide. Total body weight may be reduced, maintained or even increased; however, the body fat is reduced or body fat gain is prevented, while lean body mass is maintained or increased.
摘要翻译： 影响身体成分的方法包括使用胰岛淀粉样多肽激动剂，如普兰林肽或达瓦他汀。 总体重减轻，维持甚至增加; 然而，身体脂肪减少或身体脂肪增加被预防，而瘦体重保持或增加。
-
公开(公告)号：US20120053118A1
公开(公告)日：2012-03-01
申请号：US13256779
申请日：2010-03-17
CPC分类号： A61K38/22
摘要： Methods for affecting body composition include the use of amylin agonists, such as pramlintide or davalintide. Total body weight may be reduced, maintained or even increased; however, the body fat is reduced or body fat gain is prevented, while lean body mass is maintained or increased.
摘要翻译： 影响身体成分的方法包括使用胰岛淀粉样多肽激动剂，如普兰林肽或达瓦他汀。 总体重减轻，维持甚至增加; 然而，身体脂肪减少或身体脂肪增加被预防，而瘦体重保持或增加。
-
公开(公告)号：US08598120B2
公开(公告)日：2013-12-03
申请号：US13364250
申请日：2012-02-01
申请人： Christopher J. Soares , Michael R. Hanley , Diana Y. Lewis , David G. Parkes , Carolyn M. Jodka , Kathryn S. Prickett , Soumitra S. Ghosh , Christine M. Mack , Qing Lin
发明人： Christopher J. Soares , Michael R. Hanley , Diana Y. Lewis , David G. Parkes , Carolyn M. Jodka , Kathryn S. Prickett , Soumitra S. Ghosh , Christine M. Mack , Qing Lin
IPC分类号： A61K38/16 , A61P3/04 , A61P5/22 , C07K14/435 , C07K19/00
CPC分类号： C07K14/575
摘要： The present invention relates to novel compounds having a function of a peptide in the amylin family, related nucleic acids, expression constructs, host cells, and processes production of the compounds. The compounds of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent metabolic disorders such as obesity, diabetes, and increased cardiovascular risk.
摘要翻译： 本发明涉及在胰岛淀粉样多肽家族中具有肽功能的新化合物，相关核酸，表达构建体，宿主细胞，并且处理化合物的生产。 本发明的化合物包括一个或多个氨基酸序列修饰。 此外，公开了治疗和预防代谢紊乱如肥胖，糖尿病和增加的心血管风险的方法和组合物。
-
4.发明授权公开(公告)号：US08497240B2
公开(公告)日：2013-07-30
申请号：US12377856
申请日：2007-08-17
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
CPC分类号： C07K14/47 , A61K38/00 , C07K14/575 , C07K14/57563 , C07K14/605 , C07K2319/00
摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢性疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
5.发明申请Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders 审中-公开胰岛淀粉样多肽和胰岛淀粉样多肽激动剂治疗精神疾病和疾病公开(公告)号：US20090181890A1
公开(公告)日：2009-07-16
申请号：US12295259
申请日：2006-10-04
CPC分类号： A61K38/22 , A61K31/5513 , A61K45/06 , A61K2300/00
摘要： Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.
摘要翻译： 公开了治疗精神疾病和病症的方法和组合物。 提供的方法通常涉及对受试者施用胰岛淀粉样多肽或胰岛淀粉样多肽激动剂以治疗精神疾病和病症，以及与精神疾病和病症相关的病症。
-
公开(公告)号：US20130137631A1
公开(公告)日：2013-05-30
申请号：US13591677
申请日：2012-08-22
申请人： Odile Esther LEVY , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra G. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
发明人： Odile Esther LEVY , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra G. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
IPC分类号： C07K14/575 , C07K7/06
CPC分类号： C07K14/575 , A61K38/00 , C07K7/06 , C07K14/605
摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
-
公开(公告)号：US08404637B2
公开(公告)日：2013-03-26
申请号：US11816095
申请日：2006-02-10
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young
CPC分类号： C07K14/575 , C07K14/605 , C07K2319/00
摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
-
公开(公告)号：US20130035294A1
公开(公告)日：2013-02-07
申请号：US13651130
申请日：2012-10-12
CPC分类号： A61K38/22
摘要： Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an NMX peptide, an FNX peptide, or an NMX receptor agonist, or analogs or derivatives thereof, to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.
摘要翻译： 公开了治疗精神疾病和病症的方法和组合物。 所提供的方法通常涉及向受试者施用NMX肽，FNX肽或NMX受体激动剂或其类似物或衍生物，以治疗精神疾病和病症，以及与精神疾病和病症相关的病症。
-
9.发明申请公开(公告)号：US20110136737A1
公开(公告)日：2011-06-09
申请号：US12377856
申请日：2007-08-17
申请人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
发明人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
IPC分类号： A61K38/22 , C07K14/645 , C07K14/605 , A61K38/26 , A61P3/10 , A61P9/00
CPC分类号： C07K14/47 , A61K38/00 , C07K14/575 , C07K14/57563 , C07K14/605 , C07K2319/00
摘要： The Present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。
-
10.发明授权Amylin agonist for treating depression, anxiety disorder and schizophrenia 失效用于治疗抑郁症，焦虑障碍和精神分裂症的胰岛淀粉样多肽激动剂公开(公告)号：US07671023B2
公开(公告)日：2010-03-02
申请号：US11910206
申请日：2006-03-31
摘要： Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.
摘要翻译： 公开了治疗精神疾病和病症的方法和组合物。 提供的方法通常涉及对受试者施用胰岛淀粉样多肽或胰岛淀粉样多肽激动剂以治疗精神疾病和病症，以及与精神疾病和病症相关的病症。
-
-
-
-
-
-
-
-
-
搜索结果
28 条记录 (耗时 0.058 秒)
